Similar studies with ribociclib (MONALEESA-2) and abemaciclib (MONARCH 3; combined with a nonsteroidal aromatase inhibitor), both of which were combined with letrozole as initial therapy for advanced breast cancer, reported median PFS of 25.3 and 28.2 months, respectively (22–24). The gene discussed is CYP19A1; the disease is breast cancer.